Vectura / Skyepharma merger inquiry

The CMA investigated the anticipated acquisition by Vectura Group plc of Skyepharma plc.

Statutory timetable

Phase 1 date Action
24 May 2016 Decision published
16 May 2016 Decision announced
27 April to 12 May 2016 Invitation to comment
27 April 2016 Launch of merger inquiry

Phase 1

FNTQ decision announced

16 May 2016: The CMA has today decided that the anticipated acquisition by Vectura Group plc of Skyepharma plc does not qualify for investigation under the merger provisions of the Enterprise Act 2002. The full text of the decision is available below.

Invitation to comment: Now closed

27 April 2016: The CMA is considering whether it is or may be the case that this transaction has resulted in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation has resulted, or may be expected to result, in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.

Launch of merger inquiry

27 April 2016: The CMA announced the launch of its merger inquiry by notice to the parties.

Contact

Please send written representations about any competition or public interest to:

Martin Hughes
Competition and Markets Authority
Victoria House
Southampton Row
London
WC1B 4AD

Martin.Hughes@cma.gsi.gov.uk

Help us improve GOV.UK

Don’t include personal or financial information like your National Insurance number or credit card details.